CD4+ T cell-induced in ammatory killing controls immune evasive tumours

[1]  Aileen W. Li,et al.  A vaccine targeting resistant tumours by dual T cell plus NK cell attack , 2022, Nature.

[2]  Charles H. Yoon,et al.  Landscape of helper and regulatory antitumour CD4+ T cells in melanoma , 2022, Nature.

[3]  Gregory M. Chen,et al.  Decade-long leukaemia remissions with persistence of CD4+ CAR T cells , 2022, Nature.

[4]  Si Ming Man,et al.  Interferon-γ primes macrophages for pathogen ligand-induced killing via a caspase-8 and mitochondrial cell death pathway , 2022, Immunity.

[5]  Xueda Hu,et al.  Pan-cancer single-cell landscape of tumor-infiltrating T cells , 2021, Science.

[6]  J. Zuber,et al.  Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumour microenvironment and cross-resistance to immunotherapy in melanoma , 2021, Nature Cancer.

[7]  Jinfang Zhu.  Faculty Opinions recommendation of Inflammatory Type 2 cDCs Acquire Features of cDC1s and Macrophages to Orchestrate Immunity to Respiratory Virus Infection. , 2021, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[8]  R. Webby,et al.  Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes , 2020, bioRxiv.

[9]  T. Tüting,et al.  The aryl hydrocarbon receptor promotes inflammation‐induced dedifferentiation and systemic metastatic spread of melanoma cells , 2020, International journal of cancer.

[10]  Gregory F. Wu,et al.  cDC1 prime and are licensed by CD4 T cells to induce anti-tumour immunity , 2020, Nature.

[11]  David R. Kelley,et al.  Solo: Doublet Identification in Single-Cell RNA-Seq via Semi-Supervised Deep Learning. , 2020, Cell systems.

[12]  Chun Jimmie Ye,et al.  Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer , 2020, Cell.

[13]  Johannes U. Mayer,et al.  Inflammatory Type 2 cDCs Acquire Features of cDC1s and Macrophages to Orchestrate Immunity to Respiratory Virus Infection , 2020, Immunity.

[14]  A. Mantovani,et al.  Diversity, Mechanisms, and Significance of Macrophage Plasticity. , 2020, Annual review of pathology.

[15]  Fabian J Theis,et al.  Generalizing RNA velocity to transient cell states through dynamical modeling , 2019, Nature Biotechnology.

[16]  Chun Jimmie Ye,et al.  Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity , 2019, Cell.

[17]  E. V. Van Allen,et al.  Genomic correlates of response to immune checkpoint blockade , 2019, Nature Medicine.

[18]  A. Butte,et al.  Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage , 2018, Nature Immunology.

[19]  A. Mildner,et al.  Developmental and Functional Heterogeneity of Monocytes. , 2018, Immunity.

[20]  B. Bogen,et al.  CD4+ T-cell-Mediated Rejection of MHC Class II-Positive Tumor Cells Is Dependent on Antigen Secretion and Indirect Presentation on Host APCs. , 2018, Cancer research.

[21]  J. Borst,et al.  CD4+ T cell help in cancer immunology and immunotherapy , 2018, Nature Reviews Immunology.

[22]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[23]  Fabian J Theis,et al.  SCANPY: large-scale single-cell gene expression data analysis , 2018, Genome Biology.

[24]  A. M. Houghton,et al.  Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma , 2018, The Journal of clinical investigation.

[25]  Angela E. Leek,et al.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.

[26]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[27]  Davis J. McCarthy,et al.  A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor , 2016, F1000Research.

[28]  J. Castle,et al.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer , 2015, Nature.

[29]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[30]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[31]  Jonathan L. Schmid-Burgk,et al.  OutKnocker: a web tool for rapid and simple genotyping of designer nuclease edited cell lines , 2014, Genome research.

[32]  Edward Y Kim,et al.  Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction. , 2014, The Journal of clinical investigation.

[33]  B. Ryffel,et al.  Collective nitric oxide production provides tissue-wide immunity during Leishmania infection. , 2014, The Journal of clinical investigation.

[34]  L. Zender,et al.  T-helper-1-cell cytokines drive cancer into senescence , 2013, Nature.

[35]  J. Landsberg,et al.  Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation , 2012, Nature.

[36]  P. Bousso,et al.  CD4+ T cells rely on a cytokine gradient to control intracellular pathogens beyond sites of antigen presentation. , 2012, Immunity.

[37]  B. Bonnotte,et al.  Th-1 Lymphocytes Induce Dendritic Cell Tumor Killing Activity by an IFN-γ–Dependent Mechanism , 2011, The Journal of Immunology.

[38]  R. Blasberg,et al.  Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts , 2010, The Journal of experimental medicine.

[39]  J. Landsberg,et al.  Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. , 2009, Cancer research.

[40]  P. Muranski,et al.  Tumor-specific Th17-polarized cells eradicate large established melanoma. , 2008, Blood.

[41]  O. Lantz,et al.  CD4 cells can be more efficient at tumor rejection than CD8 cells. , 2005, Blood.

[42]  Guttorm Haraldsen,et al.  Primary antitumor immune response mediated by CD4+ T cells. , 2005, Immunity.

[43]  Randall L. Lindquist,et al.  Visualizing dendritic cell networks in vivo , 2004, Nature Immunology.

[44]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells , 2003, The Journal of experimental medicine.

[45]  N. Restifo,et al.  Natural selection of tumor variants in the generation of “tumor escape” phenotypes , 2002, Nature Immunology.

[46]  T. Blankenstein,et al.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. , 2000, Immunity.

[47]  R. Schreiber,et al.  CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ , 1999 .

[48]  C. Lowenstein,et al.  The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.

[49]  D. Pardoll,et al.  The role of CD4+ T cell responses in antitumor immunity. , 1998, Current opinion in immunology.

[50]  F. Liew,et al.  Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. , 1990, Journal of immunology.

[51]  R. Evans,et al.  Cooperation of Immune Lymphoid Cells with Macrophages in Tumour Immunity , 1970, Nature.

[52]  G. Mackaness.  THE IMMUNOLOGICAL BASIS OF ACQUIRED CELLULAR RESISTANCE , 1964, The Journal of experimental medicine.